Castle Creek Biosciences Revenue and Competitors

Location

$419M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Castle Creek Biosciences's estimated annual revenue is currently $49M per year.(i)
  • Castle Creek Biosciences's estimated revenue per employee is $193,750
  • Castle Creek Biosciences's total funding is $419M.

Employee Data

  • Castle Creek Biosciences has 253 Employees.(i)
  • Castle Creek Biosciences grew their employee count by 1% last year.

Castle Creek Biosciences's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Associate VP, Clin OpsReveal Email/Phone
4
Sr. VP Regulatory and Quality AffairsReveal Email/Phone
5
SVP, CommercialReveal Email/Phone
6
VP Human ResourcesReveal Email/Phone
7
GM, VP U.S. ManufacturingReveal Email/Phone
8
VP Quality AssuranceReveal Email/Phone
9
VP, FinanceReveal Email/Phone
10
VP, FinanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.4M9-10%N/AN/A
#2
$7.1M4677%N/AN/A
#3
$14.4M9327%N/AN/A
#4
$0.9M60%N/AN/A
#5
$1.6M1043%N/AN/A
#6
$11.5M746%N/AN/A
#7
$0.9M1122%N/AN/A
#8
$3.7M24-8%N/AN/A
#9
$2M1318%N/AN/A
#10
$9.3M602%N/AN/A
Add Company

What Is Castle Creek Biosciences?

Castle Creek Biosciences, Inc. is a privately-held, clinical-stage cell and gene therapy company advancing innovative personalized therapies for underserved disorders with high unmet medical needs.

keywords:N/A

$419M

Total Funding

253

Number of Employees

$49M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Castle Creek Biosciences News

2022-04-20 - Worldwide Adoptive Cell Therapy Industry to 2030 - Featuring ...

Novartis AG. Gilead Sciences, Inc. Castle Creek Biosciences, Inc; Lineage Cell Therapeutics, Inc. Transgene SA; Cellectis; ImmunityBio, Inc...

2022-04-06 - Dystrophic Epidermolysis Bullosa Treatment Market Report ...

... Treatment Market Report Covers Future Trends With Research 2022 to 2029 – Krystal Biotech, Castle Creek Biosciences, Abeona Therapeutics.

2022-03-30 - Evozyne Announces Multi-Target Research Collaboration and ...

... founded by Paragon Biosciences, announced today that it has ... The company's current portfolio includes Castle Creek Biosciences,...

2021-09-29 - Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

EXTON, Pa., Sept. 29, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, toda ...

2020-03-25 - Castle Creek Biosciences Raises $75M in Funding

Castle Creek Biosciences, Inc., an Exton, Pa.-based late-stage gene therapy company, received $75m in equity and debt funding. Paragon Biosciences led the $55m equity investment with participation from Fidelity Management & Research Company and Valor Equity Partners. A $20m venture loan was pro ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.3M26532%N/A
#2
$65.2M31620%N/A
#3
$58.2M32129%N/A
#4
$102.6M3275%N/A
#5
$148.8M36323%N/A